New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2014
15:59 EDTAMZN, X, AAPL, TSLA, GOOG, GILD, TWTR, FB, COptions Update; July 11, 2014
iPath S&P 500 VIX Short-Term Futures down 33c to 28.25. Option volume leaders: AAPL C GILD X FB GOOG AMZN TWTR TSLA according to Track Data.
News For AAPL;C;GILD;X;FB;GOOG;AMZN;TWTR;TSLA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | all recent news | >>
July 16, 2015
09:35 EDTC, FB, AAPLActive equity options trading on open
Subscribe for More Information
09:22 EDTGILDBristol-Myers says EU approves Evotaz for treatment of HIV-1 infection in adults
Subscribe for More Information
09:08 EDTCOn The Fly: Pre-market Movers
Subscribe for More Information
08:58 EDTCCiti says 'tracking well' to 2015 financial targets
Citigroup says "tracking well" to its 2015 financial targets, with modest revenue growth and positive operating leverage in Citicorp; says Citicorp had efficiency ratio of 55%, Citigroup ROA of 103 bps in 1H15. Says Q2 results show continued progress in challenging environment. Says gaining wallet share, improving efficiency of core franchise, winding down non-core assets, maintaining balance sheet discipline, utilizing deferred tax assets. Comments from slides that will be presented on the Q2 earnings conference call.
08:53 EDTFBFacebook to buy Pebbles for about $60M, WSJ reports
Subscribe for More Information
08:34 EDTAAPLSt. Jude Medical receives FDA approval for spinal cord stimulation trial system
St. Jude Medical (STJ) announced it received FDA approval of the Invisible Trial System. The system, which received CE Mark in June 2015, is fully wireless and leverages Apple (AAPL) technology for both the patient and physician controllers. The system is designed to provide patients a more improved and discreet spinal cord stimulation, or SCS, trial experience. "Patients undergoing SCS trials consistently tell us about challenges they find in navigating the SCS trial system, from programming the device, to discomfort from the programming cables, to management of both issues. These hindrances may impede the integration of the technology into their daily activities, which shifts their focus away from evaluating the effectiveness of SCS therapy,” said pain specialist Dr. Jason E. Pope, president of Summit Pain Alliance in Santa Rosa, California. “By providing a discreet trial system, St. Jude Medical will help patients focus more on their potential pain relief and functional improvements, and less about the burdens common to traditional trial systems.”
08:26 EDTAMZNAmazon.com shares likely to rise after Q2 results, says Oppenheimer
Subscribe for More Information
08:18 EDTAAPLSeveral stocks attractive following Intel results, says JMP Securities
For investors looking to take advantage of the sentiment shift the Intel (INTC) results could mean for the group and stronger demand due to seasonality and the Windows 10 launch, JMP Securities recommends Nvidia (NVDA) and Micron (MU). The firm says that both stocks have more attractive valuations and "more strategic roadmaps" than Intel. It also recommends Apple (AAPL) and Qualcomm (QCOM) as more attractive and secure dividend growth plays.
08:14 EDTFBFacebook faces foreign exchange headwinds in Q2, says Brean Capital
Subscribe for More Information
08:04 EDTCCiti reports Q2 Citicorp revenue $17.8B, up 2% from a year ago
Reports Q2 Global Consumer Banking revenue $8.5B. ICG revenues increased 6% from the prior year period to $8.9B. Citi Holdings revenues of $1.7B in the second quarter 2015 included CVA/DVA of $9M, compared to negative $1M in the prior year period.
08:03 EDTCCiti reports book value per share of $68.27 at end Q2
Subscribe for More Information
08:02 EDTCCiti CEO says Q2 results show 'very balanced performance' across business lines
Subscribe for More Information
08:01 EDTCCiti reports Q2 common equity tier 1 capital ratio 11.4%
Subscribe for More Information
08:00 EDTCCiti reports Q2 EPS ex-CVA/DVA $1.45, consensus $1.34
Reports Q2 revenue $19.5B, consensus $19.11B. CVA/DVA was $312M, or $196M, in the second quarter 2015, compared to negative $33M in the prior year period. Second quarter 2014 results also included the impact of a $3.8B charge, or $3.7 billion after-tax, to settle legacy RMBS and CDO-related claims.5 Excluding CVA/DVA, revenues were $19.2B, down 2% from the prior year period. Excluding CVA/DVA and the impact of the mortgage settlement in the prior year period, earnings were $1.45 per diluted share, up 17% from prior year earnings of $1.24 per diluted share. Including CVA/DVA, EPS was $1.51.
07:38 EDTGOOGGoogle July volatility elevated into Q2 and outlook
Subscribe for More Information
07:22 EDTAAPLiPhone average selling prices may be underestimated by Street, says UBS
Subscribe for More Information
07:19 EDTAAPLApple Q3 iPhone estimates raised at Stifel
Subscribe for More Information
06:58 EDTAAPLApple applies for patent for wireless devices with solar cells
Subscribe for More Information
06:46 EDTAAPLApple Watch to roll out in New Zealand July 31, AppleInsider reports
Subscribe for More Information
06:45 EDTGOOGGoogle upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Daniel Salmon upgraded Google (GOOGL, GOOG) to Outperform from Market Perform and raised his price target for the stock to $670 from $570. The search giant's Class A shares closed yesterday down 22c to $583.96. The upgrade is not a call on tonight's quarterly results, but reflects a belief that second half of 2015 and 2016 estimates will move higher on margin stabilization, Salmon tells investors in a research note. A focus on investing in key growth areas coupled with a steady revenue outlook should drive Google shares higher, the analyst writes.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use